Abstarct
Background Treatment Adherence among Tuberculosis (TB) patients is a critical challenge globally and in India. Digital technology has appeared as a tool for providing patient centric monitoring support to improve TB patients’ drug adherence. However, there is a paucity of evidence on the acceptability and effectiveness of such devices for enhancing adherence among drug-resistant TB (DRTB). The present study aims to document the feasibility of using the Tuberculosis Monitoring Encouragement Adherence Drive (TMEAD) and treatment adherence amongst DRTB patients.
Methods A longitudinal follow-up study of DRTB patients was conducted in Ahmedabad. A total of 22 Tuberculosis Units (TUs) from Ahmedabad’s rural and urban regions were included in the study based on the high load of DR-TB patients. Two hundred patients were enrolled per the inclusion criteria, and the TMEAD device was deployed to the enrolled patients and followed up monthly for six months to document drug adherence and various challenges.
Result More than 80.5% of the patients used the device, and the point drug adherence was 92% among the patients who used the device. About 19.5% did not use the device, and the reasons for the non-use of the device include non-functional devices and alarms, charging, and incomplete refilling with prescribed drugs. The other significant issues include the social stigma regarding the disease and the fear of disclosure of TB.
Conclusion The present study revealed that the acceptability of TMEAD and patient reported drug adherence were high. However, there were various disease and device related challenges. The implementation of TMEAD can be improved through the design modification. Further large-scale research is required to document the effectiveness of the device and scale up.
Competing Interest Statement
NH and RD were employed by SenseDose Technologies. SR, RP, and MJ were employed by the India Health Fund. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding Statement
The research is supported by India Health Fund a TATA Trust Initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Technical Appraisal Committee for Health Technology Assessment of the Department of Health Research, New Delhi and the Institutional Ethics Committee of the Indian Institute of Public Health, Gandhinagar, vide TRC-IEC No: 02/2020-21 dated 29 May 2020. The patients/participants provided their written informed consent to participate in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
Data from this study will be available at the Indian Institute of Public Health Gandhinagar (IIPHG), India, after the completion of this study. Researchers who meet the criteria for access to confidential data are encouraged to approach Dr. Somen Saha (ssaha@iiphg.org).
